Konofal Eric, Benzouid Cherine, Delclaux Christophe, Lecendreux Michel, Hussey Elizabeth
Pediatric Sleep Disorders Center, Hôpital Robert Debré, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France.
Department of Physiology, Hôpital Robert Debré, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France; Cardiology Unit, Hôpital Robert Debré, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France.
Sleep Med. 2017 Jun;34:168-169. doi: 10.1016/j.sleep.2017.02.020. Epub 2017 Mar 18.
Mazindol is an imidazo-isoindole derivative, a tricyclic compound and a non-amphetamine central nervous system stimulant that blocks dopamine and norepinephrine reuptake. Mazindol was withdrawn from the US and European markets in 1999 for reasons unrelated to its efficacy or safety around a time when other anorexic drugs were found to be associated with the development of pulmonary arterial hypertension (PAH). Despite the use of mazindol for decades, reports of PAH due to mazindol intake have been extremely rare. Recent interest on mazindol has emerged for the treatment of narcolepsy and attention-deficit/hyperactivity disorder. Therefore, an updated understanding of the potential benefits and risks of mazindol in these patient populations is warranted.
